Why NuPathe, Galena Biopharma, and Bitauto Holdings Are Today's 3 Best Stocks

It was another day of generally good economic data, but one bad apple spoiled the bunch for the broad-based S&P 500 (SNPINDEX: ^GSPC  ) .

Unsurprisingly, U.S. jobs data continues to point toward an improving long-term outlook. The ADP employment report, released before the opening bell today, showed that 238,000 private-sector jobs were created in December, well ahead of market expectations for about 35,000 fewer jobs to be created. This was also up from the revised November ADP employment figure of 229,000. If these figures continue to top 200,000, there's a good shot that the U.S. unemployment rate can dip below 7%.

The Mortgage Brokers Association also delivered impressive news when it reported that loan origination activity increased 2.6% in the past week. This comes on the heels of loan originations hitting more than a decade low last week. Consumers need to realize that even with rates up roughly 1% from their all-time lows, they are still historically attractive.

That one tidbit that sent the S&P 500 to its fourth loss in five days in 2014 was cautious December commentary from the Federal Open Market Committee, which stated that it wanted to ease back on its monetary stimulus very slowly. Last month, investors took the sign of tapering to mean that the U.S. economy was roaring back on all cylinder. The release today of minutes from the Fed's December meeting merely reinforces that the central bank still views the U.S. economy as a bit fragile.

By day's end, the S&P 500 moved fractionally lower by 0.39 points (-0.02%) to close at 1,837.49.

Topping all stocks today with a gain of 35.6% was neurologic and psychiatric-focused drug developer NuPathe (UNKNOWN: PATH.DL  ) . The company jumped following word that Teva Pharmaceutical (NYSE: TEVA  ) has offered to pay $150 million, or $3.65 per share, to acquire NuPathe, plus an additional $3.15 per share if certain sales goals for the FDA-approved migraine medication Zecuity are met. Last month, Endo Health Solutions bid $105 million, plus $3.15 per share in milestone incentives, for NuPathe. Although NuPathe's board has yet to determine if Teva's bid is superior, I can pretty much tell you based on investors' reaction today that it is! I find it unlikely that Endo will get into a bidding war with Teva at this point. Adding another FDA-approved drug to its branded drug portfolio for relatively little out-of-pocket cash would be a smart move for Teva.

Sticking with the biotech sector, cancer-focused biopharmaceutical company Galena Biopharma (NASDAQ: GALE  ) gained 16.4% after announcing the first enrollment of a patient in its phase 2 clinical trial for immunotherapy GALE-301. Immunotherapy treatments (which retrain the body's immune system to recognize and attack cancer cells) are one of a few highly encouraging new ways to fight cancer, and shareholders are obviously excited about this midstage study kicking off. On the heels of this news, both Maxim Group and Piper Jaffray boosted their price targets on Galena. Still, with few near-term catalysts on the horizon, I'd suggest taking a more cautious wait-and-see approach with Galena.

Finally, Bitauto Holdings (NYSE: BITA  ) rallied 14.8% despite a lack of news specific to the Internet-based content and marketing service company for the automotive industry. Nonetheless, it isn't difficult to understand why Bitauto's stock is off to the races given that China's auto market is the fastest growing in the world. With U.S. and Japanese automakers clamoring for a taste of China's growth, Bitauto could be on pace to deliver 30%-plus growth for years to come. Consider it a name worth watching.

Tired of not seeing your stocks among the days top performers? Perhaps you aren't thinking far enough outside the box!
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen 6 picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 08, 2014, at 10:25 PM, bigmac7406 wrote:

    Catalysts which could drive Gale share price up in the short term.

    - Increased Institutional Holding

    - Abstral Potential

    - Valuation

    - Yet another reputable financial analyst will support Gale.

    - Gale will announce full enrollment of Phase 2 clinical Trials of Folate Binding Protein for ovarian cancer.

    - Gale will announce full enrollment of Phase 3 NeuVax clinical trial.

    - The 70 events on Phase 3 NeuVax will be reached. Interim reports on NeuVax are good.

    - NeuVax Phase 2b (NeuVax + Herceptin) will yield results comparable to Phase 2.

    - Gale will report exceptional good sales data for Q4 of 2013.

    - Yet another short squeeze.

    This will all happen in the next 90 days.

    I believe that the share price is still cheap. This stock could make long term investors a fortune.

  • Report this Comment On January 09, 2014, at 4:04 AM, drama99 wrote:

    Long GALE Short Motley Fool

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2788232, ~/Articles/ArticleHandler.aspx, 9/1/2014 3:37:01 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement